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The Philadelphia (Ph
1) chromosome arising from the reciprocal t(9;22) translocation is found in more than 90% of chronic
myeloid leukemia (CML) patients and results in the formation of the chimeric fusion gene BCR-ABL. However, a small proportion
of patients with CML have simple or complex variants of this translocation, involving various breakpoints in addition to 9q34 and
22q11.WereportﬁveCMLcases carryingvariantPhtranslocationsinvolvingbothchromosomes 9and22aswellaschromosomes
3, 5, 7, 8, or 10. G-banding showed a reciprocal three-way translocation involving 3q21, 5q31, 7q32, 8q24, and 10q22 bands. BCR-
ABL fusion signal on der(22) was found in all of the cases by FISH.
Copyright © 2009 Ana Valencia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Chronic myelogenous leukemia (CML) is characterized by
the Philadelphia chromosome (Ph1), resulting from a bal-
anced translocation between the long arms of chromosome
9 and 22, the t(9;22)(q34;q11.2) [1]. In the formation of
the Ph1 chromosome, the 3  region of the c-ABL oncogene
is transposed from 9q34 to the 5  region of the BCR gene
on chromosome 22 to form a fusion gene BCR-ABL,w h i c h
encodes a fusion protein with constitutive tyrosine kinase
activity [2]. Although the vast majority of patients with
CML show the classical t(9;22)(q34;q11.2) translocation,
v a r i a n tP ht r a n s l o c a t i o n sa r ep r e s e n ti n5 % – 1 0 %o fC M L
cases. These are cytogenetically classiﬁed as simple variants
involving chromosome 22 and a chromosome other than 9,
and complex variants that involve chromosomes 9, 22, and
one or more other chromosomes [3]. In almost all the cases
with variant Ph1 chromosome, the BCR-ABL rearrangement
can be detected by molecular methods or by ﬂuorescence in
situ hybridization (FISH).
In this work, we described ﬁve patients diagnosed with
CML carrying diﬀerent complex variant Ph translocations
involving chromosomes 9, 22 as well as one other chromo-
some. They were studied by G-banding, FISH, and reverse
transcription-polymerase chain reaction (RT-PCR).
2.MaterialandMethods
2.1. Patients. Between March 1999 and November 2005, 81
CML patients were diagnosed in our laboratory. Informed
consent was obtained from the patient or the patient’s
guardians in accordance with the Declaration of Helsinki,
and the study was approved by the local ethical committee.
Ofthem,ﬁvepatients(6%)showedvariantPhtranslocations
involving chromosomes 3, 5, 7, 8, or 10. Main clinical
characteristics of these patients are presented in Table 1.
2.2. Cytogenetic Study. Conventional cytogenetic analysis
was performed on unstimulated 24-hour culture of a
bone marrow (BM) specimen. The cells were cultured and
processed by conventional methods, and the chromosomes
were stained with trypsin-Giemsa banding (GTG-banding).
The karyotype was described according to the International2 Advances in Hematology
System for Human Cytogenetic Nomenclature (ISCN, 2005)
[4].
2.3. FISH Analysis. FISH analysis was performed on pre-
pared slides of methanol/acetic-ﬁxed BM cells using the
BCR/ABL extra signal (ES) dual-color probe kit (Vysis Inc.,
D o w n e r sG r o v e ,I L ) .B r i e ﬂ y ,f r e s hs l i d e sw e r ep r e p a r e d
from the cytogenetic pellet stored in ﬁxative at −20
oCa n d
dehydratedwithethanol.Probesandslideswerecodenatured
at 75
oC for 1 minute and cohybridized overnight at 37
oCi n
a HYBrite denaturation/hybridization system (Vysis). Slides
were washed and counterstained with 4 -6-diamidino-2-
phenylindole (DAPI) stain. Fluorescent signals were visual-
ized under a Nikon Eclipse E600 microscope (Nikon, Tokyo,
Japan)equippedwithaCCDcameraandanalyzedusingISIS
image analysis software (Metasystems Inc., Germany).
2.4. Quantitative, Real-Time, Reverse Transcriptase Poly-
merase Chain Reaction (QT-RT-PCR) of the Chimeric BCR-
ABL Transcript. RNA was extracted from BM cells of the
patient using the MagNa Pure LC mRNA HS kit (Roche
Diagnostics GmbH Mannheim, Germany) automated on the
MagNa Pure robot (Roche Diagnostics GmbH Mannheim).
Reverse transcription was performed in a ﬁnal volume of
25μL, following the manufacturer’s instructions (TaqMan
Reverse Transcription Reagents, Applied Biosystems, Foster
City,CA).AftercDNAsynthesis,QT-RT-PCRwasperformed
to detect chimeric transcripts derived from the translocation
t(9;22).QT-RT-PCRassayswerecarriedoutwithLightCycler
(Roche Diagnostics GmbH Mannheim), using LightCycler
Fast Start DNA Master hybridization Probes (Roche Diag-
nostics GmbH Mannheim). For detecting BCR/ABL fusion
transcript, the samples were analyzed using the primers
and speciﬁc labeled probes described by Bolufer et al.
[5]. BCR/ABL ampliﬁed products were normalized to ABL
ampliﬁcationsforeachsampleusingtheprimersA2andCA3
described by Cross et al. [6].
3. Results
The group of ﬁve patients consisted of 3 females and 2
males, ranging in age at diagnosis from 50 to 75 years.
All the patients were in chronic phase at presentation
and were treated accordingly to what was considered the
standard treatment in each moment receiving hydroxyurea,
interferon-α and imatinib. One patient underwent autolo-
gous peripheral blood stem cell transplantation after failure
of interferon-α.
Cytogenetic analysis by G-banding revealed the presence
of ﬁve reciprocal three-way variant translocations of the
classical t(9;22)(q34;q11). The chromosome breakpoints
involved in these complex variant translocations were the
following: 3q21, 5q31, 7q32, 10q22 and 8q24 (Figure 1).
In addition, patients (a) and (d) also present additional
abnormalities: patient (a) showed a complex karyotype with
at least two main unrelated clones, whereas patient (d)
showed numerical abnormalities of chromosomes 15 and
22. BCR/ABL dual-color FISH demonstrated in all cases
5 9 22
t(5; 9; 22)(q31; q34; q11)
(a)
91 0 2 2
t(9; 22; 10)(q34; q11; q22)
(b)
79 2 2
t(7; 9; 22)(q32; q34; q11)
(c)
39 2 2
t(3; 9; 22)(q21; q34; q11)
(d)
89 2 2
t(8; 9; 22)(q24; q34; q11)
(e)
Figure 1: Partial karyotypes of the variant translocations. The
letters correspond to the various patient cases.
the usual pattern of BCR/ABL fusion gene on the Ph1
chromosome (not shown) that presents the usual 22q mor-
phology. In spite of the complexity of these translocations,
deletions adjacent to the t(9;22) breakpoint on the derivative
chromosome 9 were not detected. Further characterization
of the chimeric BCR-ABL transcript by QT-RT-PCR detected
the b3a2 fusion transcript in all the patients. These results
of cytogenetic and molecular analysis are summarized in
Table 2.
At present, all the patients are doing well in hematolog-
ical and complete cytogenetic remission following standard
dose imatinib treatment, except for patient (a) who died of
congestive heart failure not related with imatinib treatment.
Patients (d) and (e) showed complete disappearance ofAdvances in Hematology 3
Table 1: Clinical characteristic of the patients. M: male, F: female, WBC: white blood cell count, PLT: platelet count, BM: bone marrow, Eo:
eosinophils, Bso: basophils, HU: hydroxyurea, IFNα: interferon α, Auto: autologus, PBSC: peripheral blood stem cell transplantation.
Case Sex/Age WBC (109/L) PLT (109/L) BM Blasts (%) BM Eo/Bso (%) Phase at
diagnosis Treatment Follow-up
(months)
(a) M/75 306 390 0 6/1 Chronic HU, imatinib 30
(b) F/50 671 408 2 11/2 Chronic HU, imatinib +12
(c) F/59 123 250 0 — Chronic HU, imatinib +18
(d) M/56 431 222 0 5/0 Chronic
HU,
auto-PBSC,
IFNα, imatinib
+71
(e) F/71 689 479 2 5/2 Chronic HU, imatinib +86
Table 2: Cytogenetic and molecular results.
Case Karyotype 5  ABL
deletions RT-PCR BCR-ABL/ABL
(%) diagnosis
BCR-ABL/ABL (%)
after imatinib
(a)
46, XY, t(5;9;22)(q31;q34;q11)[5]/45, X, idem,
−Y[4]/46, X, idem, +8[3]/46, XY, +8, t(5;9;22)[2]/46,
XY, −4, t(5;9;22), −7, +der(X)? t(X;1)(p11.4;q21),
+mar[6]
NO b3a2 11.09 0.11
(b) 46, XX, t(9;22;10)(q34;q11;q22)[20] NO b3a2 1.75 0.014
(c) 46, XX, t(7;9;22)(q34;q11;q32)[25] NO b3a2 13.56 0.004
(d) 45, XY, t(3;9;22)(q21;q34;q11), −15[4]/46, XY, idem,
+22[4]/46, XY[1] NO b3a2 11.06 Negative
(e) 46, XX, t(8;9;22)(q24.1;q34;q11)[20] NO b3a2 N.A Negative
the fusion transcript after 71 and 86 months of follow-
up, respectively. Patients (a)–(c) reduced the BCR-ABL
transcripts levels in more than 2 logs (Table 2).
4. Discussion
In the present report we analyzed ﬁve patients with CML
carrying complex Ph1 translocations involving various part-
ner chromosomes by cytogenetics, FISH, and molecular
methods. In each case, chromosomal translocations lead
to a BCR-ABL fusion, as occurs in the standard t(9;22)
translocation [2]. The third chromosome present in each
of these variant translocations is known to be implicated
in some cases of Ph-positive CML cases. Besides, the
involvement of bands 3q21 (3 cases), 5q31 (2 cases), 7q32
(1 case), 8q24 (3 cases), and 10q22 (9 cases) had also been
previously reported in other cases of CML [7]. Nevertheless,
it becomes diﬃcult to report the exact number of cases
with such complex translocations due to the large amount
of variability in cytogenetics nomenclature observed before
ISCN, 2005.
Evaluationoftheprognosticsigniﬁcanceofthesetranslo-
cations has been analyzed in case reports or small series
giving controversial results. However, it has been recently
reported that patients with variant translocations have a
similar prognosis to those with classical Ph1 translocations
when treated with imatinib mesylate [8–10]. In our series,
all the patients are at present in hematological and complete
cytogenetic remission following standard-dose imatinib
treatment after 12 to 86 months of follow-up. Regarding
molecular remission, patients (d) and (e) showed complete
disappearance of the fusion transcript after 71 and 86
months, respectively. Patients (a)–(c) did not reach complete
disappearance of the fusion transcript but reduced the levels
in more than 2 logs. Patient (a) showed a lighter reduction
probably due to the complex karyotype at diagnosis.
Deletions of der(9) have been recognized in 10%–15% of
patientsinthechronicphase,beingmorefrequentlyfoundin
variant translocations. These deletions are thought to occur
at the time of the Ph1 translocation and are known to be
associated with a worse survival [11] .H o w e v e r ,ar e c e n t
studyhassuggestedthatimatinibmesylatemayovercomethe
adverse prognostic signiﬁcance of der(9) deletions [12]. In
our study, none of the patients had a deletion of a sizable
portion on the derivative chromosome 9.
In conclusion, we described ﬁve low-frequency complex
variant t(9;22) translocations representing 6% of the CML
cases diagnosed in our center during approximately seven-
year period. Despite low numbers, in our experience patients
carrying complex Ph1 translocations do not diﬀer signiﬁ-
cantly in hematological and clinical features from those with
standard translocation.
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